

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Karpas-422

RRID:CVCL_1325

Type: Cell Line

Proper Citation

RRID:CVCL_1325

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1325

Proper Citation: RRID:CVCL_1325

Description: Cell line Karpas-422 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:1465024](#), [PMID:2297573](#), [PMID:7849311](#), [PMID:8547074](#), [PMID:8558920](#), [PMID:9738977](#), [PMID:12169673](#), [PMID:16960149](#), [PMID:19278952](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20628145](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:23699601](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Quite popular cell line because of its resistance to chemotherapy., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Karpas-422

Synonyms: KARPAS-422, Karpas 422, KARPAS 422, Karpas422, KARPAS422, K422

Cross References: BTO:BTO_0004981, CLO:CLO_0007066, EFO:EFO_0005719, CLDB:cl2996, CLDB:cl4975, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03471099,

BioSample:SAMN10988506, cancercellines:CVCL_1325, Cell_Model_Passport:SIDM01008, ChEMBL-Cells:ChEMBL3308328, ChEMBL-Targets:ChEMBL2366368, Cosmic:907274, Cosmic:1086338, Cosmic:1329088, Cosmic:1629930, Cosmic:1714156, Cosmic:1945182, Cosmic:1995467, Cosmic:2276323, Cosmic:2297003, Cosmic:2361372, Cosmic:2437320, Cosmic-CLP:907274, DepMap:ACH-000315, DSMZ:ACC-32, DSMZCellDive:ACC-32, ECACC:06101702, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS171YVY, ENCODE:ENCBS301UOD, ENCODE:ENCBS530UDH, ENCODE:ENCBS850UIV, ENCODE:ENCBS869AAA, ENCODE:ENCBS870AAA, ENCODE:ENCBS992KXS, GDSC:907274, GEO:GSM115821, GEO:GSM201346, GEO:GSM380129, GEO:GSM552444, GEO:GSM907518, GEO:GSM1035313, GEO:GSM1059807, GEO:GSM1374588, GEO:GSM1669976, GEO:GSM3150249, IARC_TP53:27172, ICLC:HTL99023, LiGeA:CCLE_680, LINC_S_LDP:LCL-1120, PharmacDB:KARPAS422_730_2019, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_1325, PubChem_Cell_line:CVCL_1325, Wikidata:Q54899500, Ximbio:152419

ID: CVCL_1325

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260913T004644+0000

Ratings and Alerts

No rating or validation information has been found for Karpas-422.

Warning: Discontinued: DSMZ; ACC-32

Characteristics: Quite popular cell line because of its resistance to chemotherapy., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

- Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.
- Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.
- Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.
- Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.
- Donati G, et al. (2022) Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. *Molecular oncology*, 16(5), 1132.
- Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. *Science advances*, 8(39), eabq0117.
- Wenthe J, et al. (2021) Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. *Cancer immunology, immunotherapy : CII*, 70(10), 2851.
- Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.
- Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. *Cell reports*, 31(13), 107840.
- Hsu JH, et al. (2020) EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. *Cell chemical biology*, 27(1), 41.
- Bararia D, et al. (2020) Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. *Cell reports*, 31(5), 107522.
- Li M, et al. (2019) Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. *Cancer cell*, 35(6), 916.